(VIANEWS) – Shares of Arcturus Therapeutics (ARCT) dropped by a staggering 15.09% to $49.46 at 10:26 EST on Wednesday, following the last session’s upward trend. NASDAQ Composite is jumping 0.03% to $14,765.49, after two consecutive sessions in a row of gains. This seems, at the moment, a somewhat positive trend exchanging session today.

Arcturus Therapeutics’s last close was $31.31, 75.86% under its 52-week high of $129.71.


Today’s last reported volume for Arcturus Therapeutics is 936928 which is 86.1% above its average volume of 503449.

Arcturus Therapeutics’s Sales

Arcturus Therapeutics’s sales growth is a negative 34.5% for the present quarter and 321.3% for the next. The company’s growth estimates for the present quarter and the next is a negative 289.1% and a negative 129.3%, respectively.

Arcturus Therapeutics’s Revenue

Year-on-year quarterly revenue growth declined by 24.6%, now sitting on 9.54M for the twelve trailing months.


Arcturus Therapeutics’s last week, last month’s, and last quarter’s current volatility was a positive 1.27%, a negative 0.20%, and a positive 3.35%, respectively.

Arcturus Therapeutics’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.91% (last week), 3.22% (last month), and 3.35% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Arcturus Therapeutics’s stock is considered to be oversold (<=20).

Arcturus Therapeutics’s Stock Yearly Top and Bottom Value

Arcturus Therapeutics’s stock is valued at $49.46 at 10:26 EST, way under its 52-week high of $129.71 and way higher than its 52-week low of $24.87.

Arcturus Therapeutics’s Moving Average

Arcturus Therapeutics’s value is way above its 50-day moving average of $32.51 and way higher than its 200-day moving average of $43.28.

More news about Arcturus Therapeutics (ARCT).


Please enter your comment!
Please enter your name here